The size of the Europe Gastroparesis Drugs market was around USD 1.31 billion in 2020. It is expected to grow at a CAGR of 4.7% to reach USD 1.65 billion by 2025. It captures 25% of the global market.
Normal spontaneous movements of the muscles in the stomach are affected when a person is suffering from Gastroparesis often causing vomiting, improper digestion etc. Erythromycin, reglan are few drugs prescribed for the treatment.
Augmenting geriatric population, increased number of surgeries causing Gastroparesis as a side effect, growing number of people with diabetes, and introduction of new drugs in the market for controlling symptoms like nausea are the major factors driving the growth of this market.
Negative side effects of prescribed drugs, inordinate delays in regulatory approvals, and complicated diagnostic procedure are the major factors inhibiting market growth.
The market is segmented by drug type, disease class and end user. Classification by drug type entails Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections. Classification by disease class entails Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others. Idiopathic Gastroparesis lead the market in 2015 and will retain its position till 2022. Its causes are unknown. However, this condition can be managed by dietary management. Classification by end user entails Hospitals, Pharmacies, Clinics, and E-commerce.
Classification by geography entails UK, Spain, Germany, France and others. Europe is a close second by market share. UK captured largest market share in European market.
Key players in the market are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.2 Prokinetic Agents
5.1.3 Antiemetic Agents
5.1.4 Botulinum Toxin Injections
5.1.5 Y-o-Y Growth Analysis, By Drug Class
5.1.6 Market Attractiveness Analysis, By Drug Class
5.1.7 Market Share Analysis, By Drug Class
5.2 Disease Type
5.2.2 Diabetic Gastroparesis
5.2.3 Idiopathic Gastroparesis
5.2.4 Post-surgical Gastroparesis
5.2.6 Y-o-Y Growth Analysis, By Disease Type
5.2.7 Market Attractiveness Analysis, By Disease Type
5.2.8 Market Share Analysis, By Disease Type
5.3 End User
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Drug Class
126.96.36.199 By Disease Type
188.8.131.52 By End User
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Drug Class
18.104.22.168 By Disease Type
22.214.171.124 By End User
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Drug Class
184.108.40.206 By Disease Type
220.127.116.11 By End User
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allergan, Plc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)
8.3 AstraZeneca Plc.
8.4 Cadila Pharmaceuticals Ltd.
8.5 ETX Pharma, Inc
8.6 Evoke Pharma
8.7 GlaxoSmithKline Plc.
8.8 Neurogastrx, Inc.
8.9 Valeant Pharmaceuticals International, Inc.
8.10 Theravance Biopharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures